U.S. Regulators Approve Cymbalta(R) for Treatment of Generalised Anxiety Disorder (y 2)

    
    i  Koponen H., et al. Efficacy of Duloxetine for the Treatment of
       Generalized Anxiety Disorder: Implications for Primary Care
       Physicians. Primary Care Companion to The Journal of Clinical
       Psychiatry. In press 2007.
    ii  Rynn M., et al. Efficacy and Safety of Duloxetine in the Treatment of
        Generalized Anxiety Disorder: A Flexible-Dose, Progressive-Titration,
        Placebo-Controlled Trial. Depression and Anxiety. In press 2007.
    iii  Hartford J., et al. Duloxetine as an SNRI Treatment for Generalized
         Anxiety Disorder: Results from a Placebo- and Active-Controlled
         Trial. International Clinical Psychopharmacology. In press 2007.
    iv  Endicott J., et al. Duloxetine Treatment for Role Functioning
        Improvement in Generalized Anxiety Disorder: Three Independent
        Studies. The Journal of Clinical Psychiatry. In press 2007.
    v   Allgulander C., et al. Pharmacotherapy of Generalized Anxiety
        Disorder: Results of Duloxetine Treatment from a Pooled Analysis of 3
        Clinical Trials. Current Medical Research and Opinion. In press 2007.
    vi  Bymaster, FP et al. "The Dual Transporter Inhibitor Duloxetine: A
        Review of its Preclinical Pharmacology, Pharmacokinetic Profile, and
        Clinical Results in Depression." Current Pharmaceutical Design. 2005;
        11: 1475-1493.
    vii  Lieb R, Becker E and Altamura C. The epidemiology of generalised
         anxiety disorder in Europe. European Neuropsychopharmacology 2005
         Aug; 15(4): 445-52.
    viii  National Institute of Economic and Social Research. Summarized from
          the National Institute Economic Review, 194, 28 October 2005.
    ix   American Psychiatric Association. Diagnostic and Statistical Manual
         of Mental Disorders, Fourth Edition, Text Revision, p 472.
    x  Gliatto, Michael, F.  "Generalised Anxiety Disorder."  American
       Family Physicians, Vol. 62/No. 7, October 1, 2000.
    xi  Mendlowicz, Maura V. and Stein, Murray B. "Quality of Life in
        Individuals with Anxiety Disorders." American Journal of Psychiatry,
        Vol. 157/No. 5, May 2000, pp 677-678
    xii  Eric R. Henning, M.A., Cynthia L. Turk, Ph.D. , Douglas S. Mennin,
         Ph.D. , David M. Fresco, Ph.D., Richard G. Heimberg, Ph.D.
         Impairment and quality of life in individuals with generalised
         anxiety disorder. Depression and Anxiety 2006 Nov: 1091-4269
    xiii  Koponen H., et al. Efficacy of Duloxetine for the Treatment of
          Generalized Anxiety Disorder: Implications for Primary Care
          Physicians. Primary Care Companion to The Journal of Clinical
          Psychiatry. In press 2007.
    xiv  Rynn M., et al. Efficacy and Safety of Duloxetine in the Treatment
         of Generalized Anxiety Disorder: A Flexible-Dose,  
         Progressive-Titration, Placebo-Controlled Trial. Depression and
         Anxiety. In press 2007.
    xv  Hartford J., et al. Duloxetine as an SNRI Treatment for Generalized
        Anxiety Disorder: Results from a Placebo- and Active-Controlled
        Trial. International Clinical Psychopharmacology. In press 2007.
    xvi  Endicott J., et al. Duloxetine Treatment for Role Functioning
         Improvement in Generalized Anxiety Disorder: Three Independent
         Studies. The Journal of Clinical Psychiatry. In press 2007.
    xvii  Allgulander C., et al. Pharmacotherapy of Generalized Anxiety
          Disorder: Results of Duloxetine Treatment from a Pooled Analysis of
          3 Clinical Trials. Current Medical Research and Opinion.
          In press 2007.
    (Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )
    (Logo: http://www.newscom.com/cgi-bin/prnh/20040122/BILOGO )

David Shaffer, Eli Lilly and Company, +1-317-651-3710; or Ute E. Schmidt, Boehringer Ingelheim, +49-6132-77-97296/ Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO , http://www.newscom.com/cgi-bin/prnh/20040122/BILOGO , PRN Photo Desk, photodesk@prnewswire.com